BACKGROUND: Basal cell carcinomas (BCC), squamous cell carcinomas (SCC) and cutaneous malignant melanoma (MM) are solid skin cancers derived from different cell types, with different ability to metastasize. Several subtypes of integrins and matrix metalloproteinases (MMP) have been related to malignization and metastasis processes. This work aimed at a quantitative evaluation of skin cancers expressing eight integrins and MMP2 genes. METHODS: Expression of integrins and MMP2 genes was evaluated on fresh tumor biopsies from BCC, SCC and MM, and respective controls, by the reverse transcriptase polychain reaction (RT-PCR) technique. RESULTS: More than 90% tumors expressed alpha6a, beta1, beta3 and beta6 (non-melanoma), and alpha5a, alpha6a and MMP2 (MM). Up to 100% controls also expressed beta1 and beta3. The results were significant for alpha6a in BCC (p = 0.026), alpha6b in SCC (p = 0.035), alpha2a in BCC (p = 0.003), beta5 and beta6 in BCC (p = 0.005). MMP2 was expressed in 100% MM (p = 0.0004). CONCLUSION: Integrin subunits alpha2a and alpha6a would be interesting targets for BCC anti-tumor therapy, as well as alpha6b in case of SCC. The elevated number of BCC expressing alpha2 and alpha6, and of MM expressing alphav and MMP2, corroborate literature data.
BACKGROUND:Basal cell carcinomas (BCC), squamous cell carcinomas (SCC) and cutaneous malignant melanoma (MM) are solid skin cancers derived from different cell types, with different ability to metastasize. Several subtypes of integrins and matrix metalloproteinases (MMP) have been related to malignization and metastasis processes. This work aimed at a quantitative evaluation of skin cancers expressing eight integrins and MMP2 genes. METHODS: Expression of integrins and MMP2 genes was evaluated on fresh tumor biopsies from BCC, SCC and MM, and respective controls, by the reverse transcriptase polychain reaction (RT-PCR) technique. RESULTS: More than 90% tumors expressed alpha6a, beta1, beta3 and beta6 (non-melanoma), and alpha5a, alpha6a and MMP2 (MM). Up to 100% controls also expressed beta1 and beta3. The results were significant for alpha6a in BCC (p = 0.026), alpha6b in SCC (p = 0.035), alpha2a in BCC (p = 0.003), beta5 and beta6 in BCC (p = 0.005). MMP2 was expressed in 100% MM (p = 0.0004). CONCLUSION: Integrin subunits alpha2a and alpha6a would be interesting targets for BCC anti-tumor therapy, as well as alpha6b in case of SCC. The elevated number of BCC expressing alpha2 and alpha6, and of MM expressing alphav and MMP2, corroborate literature data.
Authors: Benjamin J Hackel; Richard H Kimura; Zheng Miao; Hongguang Liu; Ataya Sathirachinda; Zhen Cheng; Frederick T Chin; Sanjiv S Gambhir Journal: J Nucl Med Date: 2013-05-13 Impact factor: 10.057
Authors: Felipe V Pereira; Carla A Ferreira-Guimarães; Thaysa Paschoalin; Jorge A B Scutti; Filipe M Melo; Luis S Silva; Amanda C L Melo; Priscila Silva; Manoela Tiago; Alisson L Matsuo; Luiz Juliano; Maria A Juliano; Adriana K Carmona; Luiz R Travassos; Elaine G Rodrigues Journal: PLoS One Date: 2014-04-30 Impact factor: 3.240
Authors: Anna Goździalska; Anna Wojas-Pelc; Jagoda Drąg; Paweł Brzewski; Jerzy Jaśkiewicz; Maciej Pastuszczak Journal: Mol Biol Rep Date: 2016-07-12 Impact factor: 2.316
Authors: Richard H Kimura; Ling Wang; Bin Shen; Li Huo; Willemieke Tummers; Fabian V Filipp; Haiwei Henry Guo; Thomas Haywood; Lotfi Abou-Elkacem; Lucia Baratto; Frezghi Habte; Rammohan Devulapally; Timothy H Witney; Yan Cheng; Suhas Tikole; Subhendu Chakraborti; Jay Nix; Christopher A Bonagura; Negin Hatami; Joshua J Mooney; Tushar Desai; Scott Turner; Richard S Gaster; Andrea Otte; Brendan C Visser; George A Poultsides; Jeffrey Norton; Walter Park; Mark Stolowitz; Kenneth Lau; Eric Yang; Arutselvan Natarajan; Ohad Ilovich; Shyam Srinivas; Ananth Srinivasan; Ramasamy Paulmurugan; Juergen Willmann; Frederick T Chin; Zhen Cheng; Andrei Iagaru; Fang Li; Sanjiv S Gambhir Journal: Nat Commun Date: 2019-10-14 Impact factor: 14.919